These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971 [TBL] [Abstract][Full Text] [Related]
29. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175 [TBL] [Abstract][Full Text] [Related]
30. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma. Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882 [TBL] [Abstract][Full Text] [Related]
33. CD73: an emerging checkpoint for cancer immunotherapy. Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045 [TBL] [Abstract][Full Text] [Related]
34. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Reinhardt J; Landsberg J; Schmid-Burgk JL; Ramis BB; Bald T; Glodde N; Lopez-Ramos D; Young A; Ngiow SF; Nettersheim D; Schorle H; Quast T; Kolanus W; Schadendorf D; Long GV; Madore J; Scolyer RA; Ribas A; Smyth MJ; Tumeh PC; Tüting T; Hölzel M Cancer Res; 2017 Sep; 77(17):4697-4709. PubMed ID: 28652246 [TBL] [Abstract][Full Text] [Related]
35. Current Immunotherapies for Glioblastoma Multiforme. Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H Front Immunol; 2020; 11():603911. PubMed ID: 33767690 [TBL] [Abstract][Full Text] [Related]
36. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938 [TBL] [Abstract][Full Text] [Related]
37. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752 [TBL] [Abstract][Full Text] [Related]
38. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. Kim M; Min YK; Jang J; Park H; Lee S; Lee CH J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638 [TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. Yeo AT; Charest A J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277 [TBL] [Abstract][Full Text] [Related]